Drug Profile
CL AT 313
Alternative Names: CL-AT-313Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Charleston Laboratories
- Class Antitussives; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Common cold; Cough; Respiratory hypersensitivity
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Common cold in USA (PO, Liquid)
- 28 Mar 2021 No recent reports of development identified for preclinical development in Cough in USA (PO, Liquid)
- 28 Mar 2021 No recent reports of development identified for preclinical development in Respiratory hypersensitivity in USA (PO, Liquid)